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In this issue, Surgical Solutions focuses  
on our trauma expertise, recent progress  
in bench research, the contributions of  
Dr. Gerald Isenberg, insights from medical 
student Zhi Ven Fong, and pays tribute to  
Dr. John Moore. A very busy issue!
I was moved by a recent editorial in the New 
England Journal of Medicine dated February 
16, 2012. In the piece entitled “What We 
Talk About When We Talk About Health Care 
Costs”, Peter Neumann of Tufts University 
quotes from the American College of 
Physicians Ethics Manual, 6th edition: 
“Physicians have a responsibility to  
practice effective and efficient health 
care and to use health care resources 
responsibly. Parsimonious care that utilizes 
the most efficient means to effectively 
diagnose a condition and treat a patient 
respects the need to use resources wisely 
and to help insure that resources are 
equitably available.”  
Webster’s dictionary defines parsimony  
as “carefulness in the expenditure of  
money or resources”. Synonyms are  
frugal, stingy or penurious. 
Neumann’s editorial is an important read 
for all in health care delivery. The debate 
about health care costs will continue. We 
recognize that non-adherence to clinical 
pathways, variations in how we treat 
patients, re-admissions, and preventable 
errors all drive up health care costs. 
In the big picture though, Neumann nails 
the issue… “The problem is that no one in 
charge seems willing to acknowledge that 
getting a handle on cost growth will also 
involve uncomfortable trade-offs. We cannot 
as a society provide patients with unlimited 
access and unlimited choice. Providing 
better-quality care, though it is vital, won’t 
change that reality.”  
When it comes to diagnosing and treating 
cancer, early detection is important. While 
other cancers can be identified through 
routine screenings, pancreatic cancer has been 
notoriously difficult to diagnose early. After 
pancreatic cancer is diagnosed, the optimal 
course of treatment is not always clear. 
Hwyda Arafat, MD, PhD, Associate Professor 
of Surgery at Thomas Jefferson University and 
co-director of the Jefferson Pancreatic, Biliary 
and Related Cancers Center, and Jordan M. 
Winter, MD, Assistant Professor of Surgery, 
are working to change that.
Together with Mon-Li Chu, PhD, Professor 
and Vice Chair of the Department of 
Dermatology and Cutaneous Biology, Dr. 
Arafat has identified a protein – Collagen 
6A3 – that is highly expressed in cancerous 
pancreatic tissue and can be identified through 
a noninvasive blood test. 
Based on their initial findings, Dr. Arafat and 
Dr. Chu were awarded a $200,000 grant from 
the University City Science Center’s QED 
Proof of Concept Program. The team is using 
the money to validate their initial findings 
and to begin commercializing the test – “The 
COL6A3 Panel” – which is poised to become 
the first clinically reliable test for pancreatic 
ductal adenocarcinoma.
“We are exploring how this test could be used 
to monitor high-risk patient groups, such as 
those with chronic pancreatitis and those with a 
family history of pancreatic cancer,” Dr. Arafat 
explains. “This noninvasive test could also 
help in differentiating between malignant and 
benign tumors identified in imaging studies, 
and could be used to monitor pancreatic cancer 
patients as they undergo treatment.”
As Dr. Arafat works to develop a screening 
test, Dr. Winter is working to identify more 
effective prognostic tools. His work has 
explored the linkage between two proteins, 
MUC-1 and mesothelin, and pancreatic 
tumors with particularly aggressive biology. 
More specifically, Dr. Winter and his team are 
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Drs. Jordan Winter and Hwyda Arafat are key players in the world class pancreatic cancer 
research team that has been assembled at Jefferson over the last six years. 
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Gerald A. Isenberg, MD, FACS 
As Professor of Surgery, Division of 
Colorectal Surgery; Director, Surgical 
Undergraduate Education, Jefferson Medical 
College (JMC); Program Director, Colorectal 
Residency Program, Thomas Jefferson 
University Hospital; and Chair, Curriculum 
Committee, JMC, Gerald A. Isenberg, 
MD, FACS, is equally focused on – and 
passionate about – clinical practice and 
medical education. 
Indeed, as he reflects on his career at 
Jefferson, which spans nearly 25 years, Dr. 
Isenberg is appreciative of the opportunity to 
build a busy and vibrant colorectal surgery 
practice. But he clearly also values his 
experiences as an educator – particularly 
the many opportunities to lead and innovate.
In years past, Dr. Isenberg spearheaded 
the adoption of Problem-Based Learning, 
a teaching method designed to strengthen 
students’ critical-thinking skills. He also 
chaired a taskforce that explored the topic of 
professionalism and developed a blueprint 
for infusing professionalism throughout the 
curriculum. 
About 10 years ago, Dr. Isenberg created a 
fourth-year course, “Scientific Foundations 
of Clinical Medicine,” in which students 
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revisit some of the basic sciences they learned 
early in medical school and explore how they 
apply to clinical medicine. These days, Dr. 
Isenberg is part of a team that’s exploring 
health information technology and its impact on 
medical education and the practice of medicine. 
“As a teacher, I continue to emphasize the 
importance of critical thinking,” Dr. Isenberg 
says. “The information explosion in medicine 
makes it impossible to assimilate all medical 
knowledge. Instead, I focus on planting seeds – 
teaching students how to nurture and fine-tune 
their reasoning skills.” 
exploring a possible correlation between CA 
15-3, a serum marker already used in treating 
patients with metastatic breast and ovarian 
cancer, and high expression of MUC-1. 
“No one had looked at using CA 15-3 in 
patients with pancreatic cancer, probably 
because this marker won’t be elevated in 
all pancreatic cancer patients,” Dr. Winter 
explains. “However, if we find a reliable 
correlation between CA 15-3 and MUC-1, 
testing CA 15-3 levels may have a role in 
pancreatic cancer treatment.” 
What’s more, Dr. Winter is collaborating with 
Jonathan R. Brody, PhD, J. Wallace Davis and 
Gail G. Davis Professor of Surgery, to research 
gene therapies targeting pancreatic cancer 
at a molecular level: “What we imagine is a 
clinical paradigm where we can identify which 
patients are most appropriate for gene therapy 
based on the results of their serum test,” Dr. 
Winter says. 
Watch Drs. Arafat and Winter discuss 
their research projects at last year’s patient 
symposium: www.jeffersonhospital.org/
pancreasevent
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